Skip to main content

letter

. 1993 Apr;67(4):865–867. doi: 10.1038/bjc.1993.159

Adoptive tumour immunotherapy using human CD4+ T-cells.

J E Gold, M E Osband

PMCID: PMC1968373 PMID: 8097105

865

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Nakamura Y., Tokuda Y., Iwasawa M., Tsukamoto H., Kidokoro M., Kobayashi N., Kato S., Mitomi T., Habu S., Nishimura T. Large-scale culture system of human CD4+ helper/killer T cells for the application to adoptive tumour immunotherapy. Br J Cancer. 1992 Jul;66(1):20–26. doi: 10.1038/bjc.1992.210. [DOI] [PMC free article] [PubMed] [Google Scholar]
Osband M. E., Lavin P. T., Babayan R. K., Graham S., Lamm D. L., Parker B., Sawczuk I., Ross S., Krane R. J. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet. 1990 Apr 28;335(8696):994–998. doi: 10.1016/0140-6736(90)91064-h. [DOI] [PubMed] [Google Scholar]
Panzer S., Geller R. L., Bach F. H. Purified human T cells stimulated with cross-linked anti-CD3 monoclonal antibody OKT3: rIL-1 is a co-stimulatory factor for CD4+CD29+CD45RA- T cells. Scand J Immunol. 1990 Oct;32(4):359–371. doi: 10.1111/j.1365-3083.1990.tb02930.x. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES